164 related articles for article (PubMed ID: 37279819)
1. Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Merenzon MA; Hincapie Arias E; Bhatia S; Shah AH; Higgins DMO; Villaverde M; Belgorosky D; Eijan AM
Nitric Oxide; 2023 Sep; 138-139():10-16. PubMed ID: 37279819
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration.
Zhuang T; Chelluboina B; Ponnala S; Velpula KK; Rehman AA; Chetty C; Zakharian E; Rao JS; Veeravalli KK
BMC Cancer; 2013 Dec; 13():590. PubMed ID: 24325546
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
[TBL] [Abstract][Full Text] [Related]
5. Targeting iNOS As a Valuable Strategy for the Therapy of Glioma.
Maccallini C; Gallorini M; Cataldi A; Amoroso R
ChemMedChem; 2020 Feb; 15(4):339-344. PubMed ID: 31851765
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
Maccallini C; Di Matteo M; Gallorini M; Montagnani M; Graziani V; Ammazzalorso A; Amoia P; De Filippis B; Di Silvestre S; Fantacuzzi M; Giampietro L; Potenza MA; Re N; Pandolfi A; Cataldi A; Amoroso R
Eur J Med Chem; 2018 May; 152():53-64. PubMed ID: 29689474
[TBL] [Abstract][Full Text] [Related]
8. Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.
Yin JH; Yang DI; Chou H; Thompson EM; Xu J; Hsu CY
J Pharmacol Exp Ther; 2001 Apr; 297(1):308-15. PubMed ID: 11259558
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide plus 12-o-tetradecanoylphorbol 13-acetate induction of migration and invasion of glioma cells in vitro and in vivo: Differential inhibitory effects of flavonoids.
Shen SC; Lin CW; Lee HM; Chien LL; Chen YC
Neuroscience; 2006 Jun; 140(2):477-89. PubMed ID: 16580779
[TBL] [Abstract][Full Text] [Related]
10. The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.
Gallorini M; Maccallini C; Ammazzalorso A; Amoia P; De Filippis B; Fantacuzzi M; Giampietro L; Cataldi A; Amoroso R
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678338
[TBL] [Abstract][Full Text] [Related]
11. NOS Expression and NO Function in Glioma and Implications for Patient Therapies.
Tran AN; Boyd NH; Walker K; Hjelmeland AB
Antioxid Redox Signal; 2017 Jun; 26(17):986-999. PubMed ID: 27411305
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study.
Shang ZJ; Li ZB; Li JR
Int J Oral Maxillofac Surg; 2006 Jun; 35(6):539-43. PubMed ID: 16497478
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide Chronotherapy in Glioma: A Systematic Review.
Jia JL; Alshamsan B; Ng TL
Curr Oncol; 2023 Feb; 30(2):1893-1902. PubMed ID: 36826108
[TBL] [Abstract][Full Text] [Related]
14. Is There a Role for Temozolomide in Glioma Related Seizures? A Systematic Review.
Yue J; Yin C; Chen L; Xu R; Zhao D
Neurol India; 2022; 70(3):864-871. PubMed ID: 35864610
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
16. The implications of nitric oxide metabolism in the treatment of glial tumors.
Mazurek M; Rola R
Neurochem Int; 2021 Nov; 150():105172. PubMed ID: 34461111
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
19. Pathodynamics of nitric oxide production within implanted glioma studied with an in vivo microdialysis technique and immunohistochemistry.
Oyoshi T; Nomoto M; Hirano H; Kuratsu J
J Pharmacol Sci; 2003 Jan; 91(1):15-22. PubMed ID: 12686726
[TBL] [Abstract][Full Text] [Related]
20. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide.
Nakano S; Matsukado K; Black KL
Cancer Res; 1996 Sep; 56(17):4027-31. PubMed ID: 8752174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
